Treatment News : Monthly PrEP Injections Show Promise in Female Monkeys

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 4, 2014

Monthly PrEP Injections Show Promise in Female Monkeys

CROI 2014Monthly injections of the long-acting investigational antiretroviral GSK744 given to pigtail macaques prevented vaginal acquisition of SIV, which is the simian cousin of HIV. The study raises hopes that HIV-negative women may eventually have an alternative to taking daily pills for pre-exposure prophylaxis (PrEP) to prevent the spread of HIV, and one that would help address the critical issue of drug adherence. Investigators from the Centers for Disease Control and Prevention (CDC) presented their findings at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

The researchers gave injections of GSK744 to six macaques every four weeks and gave injections of a placebo to another six primates on the same schedule. All the monkeys were exposed to SIV vaginally twice a week, totaling 22 exposures in all.

All six of the primates that received the placebo injections acquired SIV, following a median of four exposures to the virus. None of the six macaques that received injections of the ARV were infected during the 22 exposures, nor did they show signs of the virus 20 weeks after the final injection of GSK744.

The study’s results, the researchers find, support human trials to study GSK744’s potential as a form of PrEP for women.

Search: PrEP, pre-exposure prophylaxis, GSK744, SIV, HIV, Conference on Retroviruses and Opportunistic Infections, CROI, Centers for Disease Control and Prevention, CROI.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Have you ever been diagnosed with diabetes or pre-diabetes?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.